A comprehensive insight into the role of molecular pathways affected by the Angiopoietin and Tie system involved in hematological malignancies' pathogenesis.

Angiogenesis has been recognized as a critical factor in developing solid tumors and hematological malignancies. How angiogenesis affects the molecular pathways in malignancies is still a mystery. The angiopoietin family, one of the known molecular mediators for angiogenesis, encourages angiogenesis by attaching to Tie receptors on cell surfaces. Angiopoietin, Tie, and particularly the molecular pathways they mediate have all been the subject of recent studies that have established their diagnostic, prognostic, and therapeutic potential. Here, we've reviewed the function of molecular pathways impacted by the Angiogenin and Tie system in hematological malignancies.

• Publication year

  2023

• Venue

  Pathology, Research and Practice

• Publication date

  2023-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.prp.2023.154677PMID 37467636
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases

  2022cited by this paper
• Novel Drugs with High Efficacy against Tumor Angiogenesis

  2022cited by this paper
• Documentation of Oncofertility Communication in Adolescents and Young Adults with Cancer: A Retrospective Analysis

  2021cited by this paper
• Targeting Tie2 in the Tumor Microenvironment: From Angiogenesis to Dissemination

  2021cited by this paper
• Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders

  2021cited by this paper
• Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

  2021cited by this paper
• The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid Malignancy

  2021cited by this paper
• Acute myeloid leukemia: current progress and future directions

  2021cited by this paper
• Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective

  2021cited by this paper
• Cancer statistics for adolescents and young adults, 2020

  2020cited by this paper
• Sulfated glycans engage the Ang/Tie pathway to regulate vascular development

  2020cited by this paper
• THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES: A REVIEW [67/135 characters].

  2020cited by this paper
• Mechanisms of new blood vessel formation and proliferative heterogeneity of endothelial cells.

  2020cited by this paper
• The Blood Circulating Rare Cell Population. What Is It and What Is It Good for?

  2020cited by this paper
• The clinical and prognostic significance of FIS1, SPI1, PDCD7 and Ang2 expression levels in acute myeloid leukemia.

  2019cited by this paper
• Angiopoietin-Tie Signaling Pathway in Endothelial Cells: A Computational Model

  2019cited by this paper
• LECT2, a Ligand for Tie1, Plays a Crucial Role in Liver Fibrogenesis.

  2019cited by this paper
• Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies

  2019cited by this paper
• The Angiopoietin ligands and Tie receptors: potential diagnostic biomarkers of vascular disease

  2019cited by this paper
• Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology

  2019cited by this paper
• Angiogenesis in 90Y-Radioembolization of Colorectal Liver Metastases.

  2019cited by this paper
• EVI‐1 modulates arsenic trioxide induced apoptosis through JNK signalling pathway in leukemia cells

  2019cited by this paper
• Anti-angiogenic Targets: Angiopoietin and Angiopoietin Receptors

  2019cited by this paper
• Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment

  2019cited by this paper
• Angiopoietin-4-dependent venous maturation and fluid drainage in the peripheral retina

  2018cited by this paper
• Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.

  2018cited by this paper
• Endothelial Tie1–mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis

  2018cited by this paper
• Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR

  2017cited by this paper
• Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and its receptor PROKR2 are associated to human colorectal cancer progression and peritoneal carcinomatosis

  2017cited by this paper
• Alteration Analysis of Bone Marrow Mesenchymal Stromal Cells from De Novo Acute Myeloid Leukemia Patients at Diagnosis

  2017cited by this paper
• Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

  2017cited by this paper
• ANGPTL4–αvβ3 interaction counteracts hypoxia‐induced vascular permeability by modulating Src signalling downstream of vascular endothelial growth factor receptor 2

  2016cited by this paper
• The progress of angiogenic factors in the development of leukemias.

  2016cited by this paper
• Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.

  2016cited by this paper
• Serum Angiopoietin Levels are Different in Acute and Chronic Myeloid Neoplasms: Angiopoietins do not only Regulate Tumor Angiogenesis

  2016cited by this paper
• Tie1 controls angiopoietin function in vascular remodeling and inflammation.

  2016cited by this paper
• Angiopoietins in the bone marrow microenvironment of acute lymphoblastic leukemia

  2016cited by this paper
• MCPH1 maintains long‐term epigenetic silencing of ANGPT2 in chronic lymphocytic leukemia

  2015cited by this paper
• The Orphan Receptor Tie1 Controls Angiogenesis and Vascular Remodeling by Differentially Regulating Tie2 in Tip and Stalk Cells

  2015cited by this paper
• Angiopoietin‐4 increases permeability of blood vessels and promotes lymphatic dilation

  2015cited by this paper
• The TIE Receptor Family

  2015cited by this paper
• Regulation of signaling interactions and receptor endocytosis in growing blood vessels

  2014cited by this paper
• Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia.

  2014cited by this paper
• Signaling Network Map of Endothelial TEK Tyrosine Kinase

  2014cited by this paper
• Angiopoietin signaling in the vasculature.

  2013cited by this paper
• Angiopoietins in angiogenesis.

  2013cited by this paper
• Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma

  2013cited by this paper
• Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy.

  2013cited by this paper
• Targeting angiopoietin-2 signaling in cancer therapy

  2013cited by this paper
• Quantification of Plasma and Bone Marrow VEGF and Angiopoietin-2 Levels in Pediatric Malignancies

  2012cited by this paper
• Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling.

  2012cited by this paper
• A Review on Angiogenesis and Its Assays

  2012cited by this paper
• Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells.

  2011cited by this paper
• High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes

  2011cited by this paper
• Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

  2011cited by this paper
• Molecular mechanisms and clinical applications of angiogenesis

  2011cited by this paper
• Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands.

  2010cited by this paper
• Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF.

  2010cited by this paper
• Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML

  2010cited by this paper
• Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features

  2010cited by this paper
• Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface

  2010cited by this paper
• Functional differences between two Tie2 ligands, angiopoietin-1 and -2, in regulation of adult bone marrow hematopoietic stem cells.

  2010cited by this paper
• Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release

  2010cited by this paper
• Molecular Mediators of Angiogenesis

  2010cited by this paper
• Roles of the receptor tyrosine kinases Tie1 and Tie2 in mediating the effects of angiopoietin-1 on endothelial permeability and apoptosis.

  2009cited by this paper
• Soluble angiopoietin-2/sTie2 receptor ratio is an independent prognostic marker in adult acute myeloid leukemia

  2009cited by this paper
• Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium

  2009cited by this paper
• Differential function of Tie2 at cell–cell contacts and cell–substratum contacts regulated by angiopoietin-1

  2008cited by this paper
• Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia.

  2008cited by this paper
• Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis.

  2008cited by this paper
• Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels

  2008cited by this paper
• Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.

  2007cited by this paper
• Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells

  2007cited by this paper
• Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia

  2007cited by this paper
• Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status

  2007cited by this paper
• Regulated Proteolytic Processing of Tie1 Modulates Ligand Responsiveness of the Receptor-tyrosine Kinase Tie2*

  2007cited by this paper
• Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status

  2006cited by this paper
• Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling.

  2006cited by this paper
• Differential levels of soluble angiopoietin‐2 and Tie‐2 in patients with haematological malignancies

  2006cited by this paper
• Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia.

  2006cited by this paper
• Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2

  2005cited by this paper
• Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia.

  2002cited by this paper
• Expression of Angiopoietin-1, Angiopoietin-2, and Tie2 Genes in Normal Ovary with Corpus luteum and in Ovarian Cancer

  2002cited by this paper
• Vascular-specific growth factors and blood vessel formation

  2000cited by this paper

• Angiopoietins: A potential therapeutic target in the treatment of diabetic nephropathy

  2025cites this paper
• Unraveling ADC resistance in hematologic malignancies: Challenges and new frontiers.

  2025cites this paper
• Research progress on the structure, function, and use of angiogenin in malignant tumours

  2024cites this paper
• Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?

  2024cites this paper
• Metabolic regulation of tumor cells exposed to different oxygenated polycyclic aromatic hydrocarbons.

  2023cites this paper